Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant doxorubicin + ifosfamide for retroperitoneal dedifferentiated liposarcoma
jRCTs041230007Phase 2Recruiting
- Start
- Apr 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin and ifosfamide in Liposarcoma. Primary endpoint: Median relapse-free survival time. Started Apr 2023; status: recruiting.
02
Drugs
doxorubicinifosfamide
03
Conditions
Liposarcoma
Beyond the preview
Go deeper on jRCTs041230007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041230007.